id: NEW:naltrexone_treatment_availability_pregnant_to_opioid_use_disorder
name: Naltrexone Treatment Availability for Pregnant Individuals â†’ Opioid Use Disorder
from_node:
  node_id: NEW:naltrexone_treatment_availability_pregnant
  node_name: Naltrexone Treatment Availability for Pregnant Individuals
to_node:
  node_id: opioid_use_disorder
  node_name: Opioid Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Limited naltrexone prescribers willing to treat pregnant patients creates treatment gap'
- 'Step 2: Pregnant individuals with OUD have reduced access to naltrexone as medication-assisted treatment
  option'
- 'Step 3: Without access to full range of MAT options, treatment may be suboptimal or inaccessible'
- 'Step 4: Continued OUD during pregnancy increases risks for mother and developing fetus'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Chloe Deflorimonte et al. 2023. "National Provider Survey: Use of Naltrexone for
    Pregnant Individuals with Substance Use Disorders." https://doi.org/10.1097/ADM.0000000000001225'
  supporting_citations:
  - Additional citations require full-text access - abstract references national registry of naltrexone
    prescribers (N=5208)
  - Additional citations require full-text access - references to national guidelines mentioned as barrier
  - Additional citations require full-text access - safety concern literature referenced
  doi: 10.1097/ADM.0000000000001225
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The survey found significant barriers to naltrexone access for pregnant individuals with
  opioid use disorder, with only about one-third of responding sites offering this treatment option. This
  limits the range of medication-assisted treatment available to pregnant patients.
quantitative_effects:
  effect_size:
    value: 35.9
    type: percentage_change
  sample_size: 78
spatial_variation:
  varies_by_geography: true
  variation_notes: Northeast United States has the most sites offering naltrexone for pregnant individuals;
    other regions have significantly fewer options
moderators:
- name: lack_of_national_guidelines
  direction: weakens
  strength: moderate
  description: Absence of national guidelines for naltrexone use in pregnancy cited by 14.1% of providers
    as barrier
- name: provider_safety_concerns
  direction: weakens
  strength: moderate
  description: Safety concerns during pregnancy reported by 9.4% of providers
structural_competency:
  equity_implications: This mechanism demonstrates how healthcare system structure and policy gaps create
    inequitable access to SUD treatment for pregnant individuals. The survey response rate (33.1%) and
    limited availability (35.9% of responders) suggest systemic underinvestment in perinatal addiction
    medicine. Structural barriers including lack of guidelines, educational gaps, and geographic maldistribution
    create a two-tiered system where pregnant individuals' treatment options depend heavily on location
    rather than clinical need.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.209891'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
